Skye Bioscience, Common Stock Current Valuation
| SKYE Stock | USD 4.28 0.21 4.68% |
Valuation analysis of Skye Bioscience, Common helps investors to measure Skye Bioscience,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value Over EBITDA is expected to grow to -1.57. The current year's Enterprise Value Multiple is expected to grow to -1.57. Fundamental drivers impacting Skye Bioscience,'s valuation include:
Price Book 1.713 | Enterprise Value 62.6 M | Enterprise Value Ebitda (2.56) |
Undervalued
Today
Please note that Skye Bioscience,'s price fluctuation is relatively risky at this time. Calculation of the real value of Skye Bioscience, Common is based on 3 months time horizon. Increasing Skye Bioscience,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Skye stock is determined by what a typical buyer is willing to pay for full or partial control of Skye Bioscience, Common. Since Skye Bioscience, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Skye Stock. However, Skye Bioscience,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.28 | Real 7.68 | Target 18.25 | Hype 4.22 |
The real value of Skye Stock, also known as its intrinsic value, is the underlying worth of Skye Bioscience, Common Company, which is reflected in its stock price. It is based on Skye Bioscience,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Skye Bioscience,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Skye Bioscience, Common helps investors to forecast how Skye stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Skye Bioscience, more accurately as focusing exclusively on Skye Bioscience,'s fundamentals will not take into account other important factors: Skye Bioscience, Common Company Current Valuation Analysis
Skye Bioscience,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Skye Bioscience, Current Valuation | 62.63 M |
Most of Skye Bioscience,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Skye Bioscience, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Skye Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Skye Bioscience, is extremely important. It helps to project a fair market value of Skye Stock properly, considering its historical fundamentals such as Current Valuation. Since Skye Bioscience,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Skye Bioscience,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Skye Bioscience,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Skye Current Valuation Historical Pattern
Today, most investors in Skye Bioscience, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Skye Bioscience,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Skye Bioscience, current valuation as a starting point in their analysis.
Skye Bioscience, Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Skye Bioscience, Common has a Current Valuation of 62.63 M. This is 99.56% lower than that of the Biotechnology sector and 98.65% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.62% higher than that of the company.
Skye Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Skye Bioscience,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Skye Bioscience, could also be used in its relative valuation, which is a method of valuing Skye Bioscience, by comparing valuation metrics of similar companies.Skye Bioscience, is currently under evaluation in current valuation category among its peers.
Skye Bioscience, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Skye Bioscience,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Skye Bioscience,'s managers, analysts, and investors.Environmental | Governance | Social |
Skye Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 62.63 M | ||||
| Shares Outstanding | 30.34 M | ||||
| Shares Owned By Insiders | 1.89 % | ||||
| Shares Owned By Institutions | 85.41 % | ||||
| Number Of Shares Shorted | 1.99 M | ||||
| Price To Book | 1.71 X | ||||
| EBITDA | (13.55 M) | ||||
| Net Income | (37.64 M) | ||||
| Cash And Equivalents | 2.93 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 0.91 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | (13.95 M) | ||||
| Short Ratio | 5.76 X | ||||
| Earnings Per Share | (3.60) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 163.52 M | ||||
| Total Asset | 11.94 M | ||||
| Retained Earnings | (104.38 M) | ||||
| Working Capital | (2.25 M) | ||||
| Net Asset | 11.94 M |
About Skye Bioscience, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Skye Bioscience, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Skye Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Skye Bioscience, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out Skye Bioscience, Piotroski F Score and Skye Bioscience, Altman Z Score analysis. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.